Tags

Type your tag names separated by a space and hit enter

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Parkinsonism Relat Disord. 2012 Nov; 18(9):1039-41.PR

Abstract

BACKGROUND

While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy.

OBJECTIVE

To assess the impact of the LRRK2 Gly2019Ser (G2019S) carrier status on the time to the onset of levodopa-induced dyskinesias (LID).

METHODS

Consecutive PD patients treated with levodopa were genotyped for the LRRK2 G2019S mutation. The relationship between mutation carrier status and the time to LID onset was explored after matching carriers to non-carriers for age at PD onset, gender, and time from PD diagnosis to levodopa initiation, using Kaplan-Meier curves and the Cox proportional hazards model, using LID onset as an end-point.

RESULTS

Overall, 349 Israeli PD patients [222 Ashkenazi-Jewish (AJ), 60.5% males, mean age at diagnosis: 60.6 ± 13.2 years] participated in the study. Of these, 33 patients (9.5%, 30 AJ) carried the LRRK2 G2019S mutation. The prevalence of LID was non-significantly higher among carriers (22/33, 66.7%) than non-carriers (168/316, 53.2%, p = 0.15). The mean duration of therapy from levodopa initiation to the development of LID or last follow-up (in cases who were LID-free) was 5.1 ± 5.4 years for carriers and 4.4 ± 4.0 years in non-carriers (p = 0.47) and the survival curves in carriers and matched non-carriers were not significantly different (Cox proportional hazards test and log-rank test; p = 0.79).

CONCLUSIONS

The LRRK2 G2019S mutation status has no discernable effect on the prevalence of LID or on LID latency in Israeli levodopa-treated PD patients.

Authors+Show Affiliations

The Parkinson Disease and Movement Disorders Clinic, Sagol Neuroscience Center and Department of Neurology, Tel Aviv University, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22703868

Citation

Yahalom, Gilad, et al. "Dyskinesias in Patients With Parkinson's Disease: Effect of the Leucine-rich Repeat Kinase 2 (LRRK2) G2019S Mutation." Parkinsonism & Related Disorders, vol. 18, no. 9, 2012, pp. 1039-41.
Yahalom G, Kaplan N, Vituri A, et al. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism Relat Disord. 2012;18(9):1039-41.
Yahalom, G., Kaplan, N., Vituri, A., Cohen, O. S., Inzelberg, R., Kozlova, E., Korczyn, A. D., Rosset, S., Friedman, E., & Hassin-Baer, S. (2012). Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism & Related Disorders, 18(9), 1039-41. https://doi.org/10.1016/j.parkreldis.2012.05.014
Yahalom G, et al. Dyskinesias in Patients With Parkinson's Disease: Effect of the Leucine-rich Repeat Kinase 2 (LRRK2) G2019S Mutation. Parkinsonism Relat Disord. 2012;18(9):1039-41. PubMed PMID: 22703868.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. AU - Yahalom,Gilad, AU - Kaplan,Natalie, AU - Vituri,Aya, AU - Cohen,Oren S, AU - Inzelberg,Rivka, AU - Kozlova,Evgenia, AU - Korczyn,Amos D, AU - Rosset,Saharon, AU - Friedman,Eitan, AU - Hassin-Baer,Sharon, Y1 - 2012/06/13/ PY - 2012/02/19/received PY - 2012/04/30/revised PY - 2012/05/18/accepted PY - 2012/6/19/entrez PY - 2012/6/19/pubmed PY - 2013/5/4/medline SP - 1039 EP - 41 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 18 IS - 9 N2 - BACKGROUND: While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy. OBJECTIVE: To assess the impact of the LRRK2 Gly2019Ser (G2019S) carrier status on the time to the onset of levodopa-induced dyskinesias (LID). METHODS: Consecutive PD patients treated with levodopa were genotyped for the LRRK2 G2019S mutation. The relationship between mutation carrier status and the time to LID onset was explored after matching carriers to non-carriers for age at PD onset, gender, and time from PD diagnosis to levodopa initiation, using Kaplan-Meier curves and the Cox proportional hazards model, using LID onset as an end-point. RESULTS: Overall, 349 Israeli PD patients [222 Ashkenazi-Jewish (AJ), 60.5% males, mean age at diagnosis: 60.6 ± 13.2 years] participated in the study. Of these, 33 patients (9.5%, 30 AJ) carried the LRRK2 G2019S mutation. The prevalence of LID was non-significantly higher among carriers (22/33, 66.7%) than non-carriers (168/316, 53.2%, p = 0.15). The mean duration of therapy from levodopa initiation to the development of LID or last follow-up (in cases who were LID-free) was 5.1 ± 5.4 years for carriers and 4.4 ± 4.0 years in non-carriers (p = 0.47) and the survival curves in carriers and matched non-carriers were not significantly different (Cox proportional hazards test and log-rank test; p = 0.79). CONCLUSIONS: The LRRK2 G2019S mutation status has no discernable effect on the prevalence of LID or on LID latency in Israeli levodopa-treated PD patients. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/22703868/Dyskinesias_in_patients_with_Parkinson's_disease:_effect_of_the_leucine_rich_repeat_kinase_2__LRRK2__G2019S_mutation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(12)00194-0 DB - PRIME DP - Unbound Medicine ER -